Literature DB >> 2447115

Dopaminergic regulation of alpha-subunit secretion and messenger ribonucleic acid levels in alpha-secreting pituitary tumors.

A Klibanski1, M A Shupnik, H A Bikkal, P M Black, B Kliman, N T Zervas.   

Abstract

Glycoprotein hormone and/or subunit secretion has been increasingly recognized in patients with pituitary nonsecretory adenomas and alpha-subunit secretion has been reported to occur in 5-10% of all pituitary tumors. We investigated the dopaminergic regulation of alpha-subunit secretion in four patients with alpha-subunit secreting pituitary adenomas documented by serum and immunocytochemical studies. In three of the four patients there was a significant decrease in serum alpha-subunit concentrations during 6 weeks of bromocriptine administration. Tumor size decreased in two patients. In pituitary tumor cells from one patient cultured in vitro, dopamine caused a highly significant decrease in media alpha-subunit concentrations. To investigate whether dopaminergic regulation of alpha-subunit secretion occurs at a pre- or posttranslational level, messenger RNA (mRNA) from cultured tumor cells from one patient was analyzed by Northern blot techniques. A decrease in alpha-subunit mRNA occurred in cells incubated with 10(-10), 10(-8), and 10(-6) M dopamine. We conclude that dopamine suppressed pituitary tumor alpha-subunit secretion and mRNA levels. Dopamine agonists may be of benefit in the therapy of patients with such tumors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2447115     DOI: 10.1210/jcem-66-1-96

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Receptor imaging in the diagnosis and treatment of pituitary tumors.

Authors:  D J Kwekkeboom; W W de Herder; E P Krenning
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

2.  Dopamine D2 receptor gene expression in human adenohypophysial adenomas.

Authors:  L Stefaneanu; K Kovacs; E Horvath; M Buchfelder; R Fahlbusch; L Lancranjan
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 3.  Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.

Authors:  Mansur E Shomali; Laurence Katznelson
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

4.  Follicle stimulating hormone-secreting pituitary adenoma: inappropriate secretion and effect of pulsatile luteinizing hormone releasing hormone analogue (buserelin) administration.

Authors:  S Damjanović; D Micić; V Popović; M Petakov; A Kendereski; M Sumarac; D Manojlović; J Mićić
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

Review 5.  Pituitary tumor diagnosis and treatment.

Authors:  Paul L Penar; David J Nathan; Muriel H Nathan; Afshin Salsali
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

Review 6.  Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas.

Authors:  C Capatina; C Poiana
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

7.  Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line.

Authors:  Paweena Chunharojrith; Yuki Nakayama; Xiaobing Jiang; Rachel E Kery; Jun Ma; Cristine S De La Hoz Ulloa; Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2015-08-15       Impact factor: 4.102

8.  Gonadotropin-releasing hormone receptor mRNA expression by human pituitary tumors in vitro.

Authors:  J M Alexander; A Klibanski
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

9.  Clinically nonfunctioning pituitary tumors are monoclonal in origin.

Authors:  J M Alexander; B M Biller; H Bikkal; N T Zervas; A Arnold; A Klibanski
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.